COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00464113
Recruitment Status : Terminated (Sponsor decision)
First Posted : April 20, 2007
Last Update Posted : August 21, 2015
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukemia Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Drug: XL228 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL)
Study Start Date : May 2007
Actual Primary Completion Date : December 2010
Actual Study Completion Date : April 2011

Arm Intervention/treatment
Experimental: 1
once-weekly dosing
Drug: XL228
1-hour IV infusion

Experimental: 2
twice-weekly dosing
Drug: XL228
1-hour IV infusion

Primary Outcome Measures :
  1. Safety, tolerability, and maximum tolerated dose of once-weekly and/or twice-weekly 1-hour intravenous (IV) infusion of XL228 [ Time Frame: Assessed at periodic visits ]

Secondary Outcome Measures :
  1. Evaluate plasma pharmacokinetics and estimate renal elimination of once-weekly and twice-weekly 1-hour IV infusion of XL228 [ Time Frame: Assessed at periodic visits ]
  2. Exploratory Outcomes: Evaluate hematologic and cytogenetic response and pharmacodynamic correlates of XL228 activity [ Time Frame: Assessed at periodic visits ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The subject has a confirmed pathologic diagnosis as evidenced by the presence of the BCR-Abl translocation [t(9;22)] by fluorescence in situ hybridization (FISH), cytogenetics, or quantitative polymerase chain reaction (QPCR) of one of the following:

    1. CML

      • Chronic phase (CP)
      • Accelerated phase (AP)
      • Blast phase (BP) OR
    2. Ph+ ALL
  2. The subject has one of the following:

    • Known T315I Abl mutation
    • Known resistance to or intolerance of imatinib and dasatinib
    • At least one prior anti-leukemia therapy, including, but not limited to, interferon, imatinib, or dasatinib
  3. The subject is at least 18 years old.
  4. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  5. The subject has adequate organ function.
  6. The subject is capable of understanding and complying with the protocol and has signed the informed consent document.
  7. Sexually active subjects must use an accepted method of contraception during the course of the study.
  8. Female subjects of childbearing potential must have a negative pregnancy test at enrollment.

Exclusion Criteria:

  1. The subject has received interferon, imatinib, or dasatinib within 7 days of the first dose of XL228.
  2. The subject has received an investigational agent or radiotherapy within 28 days of the first dose of XL228.
  3. The subject has received immunosuppressive therapy (eg, cyclosporine, steroids, tacrolimus for graft-versus-host disease [GVHD]) within 28 days prior to the first dose of XL228.
  4. The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤1 from toxicities related to peripheral stem cell or bone marrow transplant.
  5. The subject has not recovered to CTCAE v3.0 Grade ≤1 from adverse events (AEs) due to investigational drugs or other medications.
  6. The subject has known allergy or hypersensitivity to any component of the investigational drug product.
  7. The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  8. The subject is pregnant or breastfeeding.
  9. The subject is known to be positive for the human immunodeficiency virus (HIV).
  10. The subject has an inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00464113

Layout table for location information
United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095-1678
University of California San Francisco
San Francisco, California, United States, 94143-1270
United States, District of Columbia
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States, 20007
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Exelixis Identifier: NCT00464113    
Other Study ID Numbers: XL228-001
First Posted: April 20, 2007    Key Record Dates
Last Update Posted: August 21, 2015
Last Verified: August 2015
Keywords provided by Exelixis:
Myeloid Leukemia
Lymphocytic Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Translocation, Genetic
Chromosome Aberrations
Pathologic Processes